Alerce Investment Management, L.P.
Follow13F filer, CIK 1844002, Chicago, IL
Alerce Investment Management, L.P. reported $56,800,164 across 5 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000895345-25-000069
- Period
- 2024-12-31
- Reported value
- $56.8M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| VERONA PHARMA PLCreduced | -117,880 | -$5.47M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2024
Share positions as resolved from 13F-HR 0000895345-25-000069, largest first. % of portfolio is the value over $56,800,164, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| ANNXANNEXON INC | 7,406,024 | $38M | 66.89% | 0 | Timeline | ||
| AKBAAKEBIA THREAPEUTICS INC | 5,747,906 | $10.9M | 19.23% | 0 | Timeline | ||
| VERONA PHARMA PLCVERONA PHARMA PLC | 88,000 | $4.09M | 7.19% | -117,880 | |||
| AMWLAMERICAN WELL CORP | 523,785 | $3.8M | 6.69% | 0 | Timeline | ||
| WHWKWHITEHAWK THERAPEUTICS INC | 659 | $2.08K | <0.01% | 0 | Timeline |
How Q4 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000895345-25-000069 | base | 2025-02-14 | acceptance time not in the bulk data set |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000895345-25-000069 | Quarter ended 2024-12-31 | 2025-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-24-000559 | Quarter ended 2024-09-30 | 2024-11-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-24-000350 | Quarter ended 2024-06-30 | 2024-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-24-000166 | Quarter ended 2024-03-31 | 2024-05-09 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-24-000038 | Quarter ended 2023-12-31 | 2024-02-09 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-23-000616 | Quarter ended 2023-09-30 | 2023-11-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-23-000465 | Quarter ended 2023-06-30 | 2023-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-23-000288 | Quarter ended 2023-03-31 | 2023-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0000895345-23-000105 | Quarter ended 2022-12-31 | 2023-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-22-019849 | Quarter ended 2022-09-30 | 2022-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-22-000006 | Quarter ended 2022-06-30 | 2022-08-04 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-22-000005 | Quarter ended 2022-03-31 | 2022-05-13 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-22-000001 | Quarter ended 2021-12-31 | 2022-02-09 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-21-000005 | Quarter ended 2021-09-30 | 2021-11-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-21-000004 | Quarter ended 2021-06-30 | 2021-08-11 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-21-000003 | Quarter ended 2021-03-31 | 2021-05-12 | acceptance time not in the bulk data set | |
| 13F-HR 0001844002-21-000001 | Quarter ended 2020-12-31 | 2021-02-11 | acceptance time not in the bulk data set |